Identifying antibodies specific to C. difficile using advanced single-cell technology
Core 3: Single-Cell Core
This study is exploring new ways to find and understand antibodies that can fight C. difficile infections, which could lead to better treatments or vaccines for patients dealing with this harmful bacteria.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project ID | NIH-11044218 on NIH RePORTER |
What this research studies
This research focuses on developing innovative methods to discover and characterize antibodies that specifically target C. difficile, a harmful bacterium. By utilizing a cutting-edge technology called LIBRA-seq, researchers can analyze individual B cells to determine their receptor sequences and the specific antigens they recognize. This approach allows for the simultaneous examination of many B cells and diverse antigens, enhancing the efficiency of antibody discovery. Patients may benefit from the development of targeted therapies or vaccines against C. difficile infections.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have been diagnosed with C. difficile infections or are at high risk for such infections.
Not a fit: Patients who do not have C. difficile infections or are not at risk for these infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective treatments or vaccines for C. difficile infections, improving patient outcomes.
How similar studies have performed: Other research has shown success with similar antibody discovery approaches, indicating the potential for significant advancements in this area.
Where this research is happening
Nashville, United States
- Vanderbilt University Medical Center — Nashville, United States (Active)
Researchers
- Principal investigator: Georgiev, Ivelin — Vanderbilt University Medical Center
- Study coordinator: Georgiev, Ivelin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.